169 related articles for article (PubMed ID: 37541303)
1. EGFR-Induced and c-Src-Mediated CD47 Phosphorylation Inhibits TRIM21-Dependent Polyubiquitylation and Degradation of CD47 to Promote Tumor Immune Evasion.
Du L; Su Z; Wang S; Meng Y; Xiao F; Xu D; Li X; Qian X; Lee SB; Lee JH; Lu Z; Lyu J
Adv Sci (Weinh); 2023 Sep; 10(27):e2206380. PubMed ID: 37541303
[TBL] [Abstract][Full Text] [Related]
2. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC.
Nigro A; Ricciardi L; Salvato I; Sabbatino F; Vitale M; Crescenzi MA; Montico B; Triggiani M; Pepe S; Stellato C; Casolaro V; Dal Col J
Front Immunol; 2019; 10():3135. PubMed ID: 32082304
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion.
Jiang N; Xie B; Xiao W; Fan M; Xu S; Duan Y; Hamsafar Y; Evans AC; Huang J; Zhou W; Lin X; Ye N; Wanggou S; Chen W; Jing D; Fragoso RC; Dugger BN; Wilson PF; Coleman MA; Xia S; Li X; Sun LQ; Monjazeb AM; Wang A; Murphy WJ; Kung HJ; Lam KS; Chen HW; Li JJ
Nat Commun; 2022 Mar; 13(1):1511. PubMed ID: 35314680
[TBL] [Abstract][Full Text] [Related]
5. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
6. The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a.
Peluso MO; Adam A; Armet CM; Zhang L; O'Connor RW; Lee BH; Lake AC; Normant E; Chappel SC; Hill JA; Palombella VJ; Holland PM; Paterson AM
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345627
[TBL] [Abstract][Full Text] [Related]
7. Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma.
Zhang X; Chen W; Fan J; Wang S; Xian Z; Luan J; Li Y; Wang Y; Nan Y; Luo M; Li S; Tian W; Ju D
Carcinogenesis; 2018 May; 39(5):689-699. PubMed ID: 29538621
[TBL] [Abstract][Full Text] [Related]
8. Extracellular Matrix Protein Tenascin C Increases Phagocytosis Mediated by CD47 Loss of Function in Glioblastoma.
Ma D; Liu S; Lal B; Wei S; Wang S; Zhan D; Zhang H; Lee RS; Gao P; Lopez-Bertoni H; Ying M; Li JJ; Laterra J; Wilson MA; Xia S
Cancer Res; 2019 May; 79(10):2697-2708. PubMed ID: 30898840
[TBL] [Abstract][Full Text] [Related]
9. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
10. Hypoxia-induced ZEB1 promotes cervical cancer immune evasion by strengthening the CD47-SIRPα axis.
Chen XJ; Guo CH; Wang ZC; Yang Y; Pan YH; Liang JY; Sun MG; Fan LS; Liang L; Wang W
Cell Commun Signal; 2024 Jan; 22(1):15. PubMed ID: 38183060
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation.
Hendriks MAJM; Ploeg EM; Koopmans I; Britsch I; Ke X; Samplonius DF; Helfrich W
Oncoimmunology; 2020 Sep; 9(1):1824323. PubMed ID: 33299654
[TBL] [Abstract][Full Text] [Related]
12. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y
Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146
[TBL] [Abstract][Full Text] [Related]
13. CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer.
Yu WB; Chen YC; Huang CY; Ye ZH; Shi W; Zhu H; Shi JJ; Chen J; Lu JJ
Front Med; 2023 Feb; 17(1):105-118. PubMed ID: 36414917
[TBL] [Abstract][Full Text] [Related]
14. NDR1 activates CD47 transcription by increasing protein stability and nuclear location of ASCL1 to enhance cancer stem cell properties and evasion of phagocytosis in small cell lung cancer.
Wang LL; Wan XY; Wang TL; Liu CQ; Zheng FM
Med Oncol; 2022 Oct; 39(12):254. PubMed ID: 36224405
[TBL] [Abstract][Full Text] [Related]
15. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.
Lu KV; Zhu S; Cvrljevic A; Huang TT; Sarkaria S; Ahkavan D; Dang J; Dinca EB; Plaisier SB; Oderberg I; Lee Y; Chen Z; Caldwell JS; Xie Y; Loo JA; Seligson D; Chakravari A; Lee FY; Weinmann R; Cloughesy TF; Nelson SF; Bergers G; Graeber T; Furnari FB; James CD; Cavenee WK; Johns TG; Mischel PS
Cancer Res; 2009 Sep; 69(17):6889-98. PubMed ID: 19690143
[TBL] [Abstract][Full Text] [Related]
16. [Latest Findings on the Role of CD47 in Tumor Immune Evasion and Related Targeted Therapies].
Jie XL; Kong YY; Zhou GB
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):455-461. PubMed ID: 37248568
[TBL] [Abstract][Full Text] [Related]
17. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.
Dheilly E; Moine V; Broyer L; Salgado-Pires S; Johnson Z; Papaioannou A; Cons L; Calloud S; Majocchi S; Nelson R; Rousseau F; Ferlin W; Kosco-Vilbois M; Fischer N; Masternak K
Mol Ther; 2017 Feb; 25(2):523-533. PubMed ID: 28153099
[TBL] [Abstract][Full Text] [Related]
18. Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint.
Wu ZH; Li N; Mei XF; Chen J; Wang XZ; Guo TT; Chen G; Nie L; Chen Y; Jiang MZ; Wang JT; Wang HB
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256517
[TBL] [Abstract][Full Text] [Related]
19. RAGA prevents tumor immune evasion of LUAD by promoting CD47 lysosome degradation.
Zhang L; Yu J; Zheng M; Zhen H; Xie Q; Zhang C; Zhou Z; Jin G
Commun Biol; 2023 Feb; 6(1):211. PubMed ID: 36823443
[TBL] [Abstract][Full Text] [Related]
20. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
